Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 16, 2015 - Issue 17
Submit an article Journal homepage
240
Views
2
CrossRef citations to date
0
Altmetric
Reviews

Nonbiological pharmacotherapies for the treatment of diabetic macular edema

Aniruddha AgarwalOcular Imaging Research and Reading Center (OIRRC), Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA
,
Jacob ParriottCollege of Medicine, University of Nebraska, Omaha, NE, USA
,
Sibel DemirelOcular Imaging Research and Reading Center (OIRRC), Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA;Department of Ophthalmology, Ankara University Faculty of Medicine, Ankara, Turkey
,
Colby ArgoCollege of Medicine, University of Nebraska, Omaha, NE, USA
,
Yasir Jamal SepahOcular Imaging Research and Reading Center (OIRRC), Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA
,
Diana V DoOcular Imaging Research and Reading Center (OIRRC), Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA
&
Quan Dong NguyenOcular Imaging Research and Reading Center (OIRRC), Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USACorrespondence[email protected]
 show all
Pages 2625-2635 | Published online: 02 Nov 2015

Bibliography

  • Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
  • Agarwal A, Sarwar S, Sepah YJ, et al. What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era? Curr Opin Ophthalmol. 2015;26:177–183.

•This review article summarizes the lessons learnt in the management of diabetic macular edema based on the level I evidence from various large, multicenter clinical trials

  • Amoaku WM, Saker S, Stewart EA. A review of therapies for diabetic macular oedema and rationale for combination therapy. Eye. 2015. doi:10.1038/eye.2015.110.
  • Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120:2013–2022.

••This is a landmark trial that provided evidence of the safety and efficacy of ranibizumab in the treatment of diabetic macular edema

  • Do DV, Nguyen QD, Khwaja AA, et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol. 2013;131:139–145.

••This study is an extension of the pivotal clinical trial evaluating the efficacy of ranibizumab in the treatment of diabetic macular edema.

  • Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–1203.

••This is an important study providing head-to-head comparison of three anti-VEGF agents, ranibizumab, aflibercept and bevacizumab, in the management of diabetic macular edema.

  • Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130:972–979.
  • Arevalo JF. Diabetic macular edema: changing treatment paradigms. Curr Opin Ophthalmol. 2014;25:502–507.
  • Brown GC, Brown MM, Turpcu A, et al. The cost-effectiveness of ranibizumab for the treatment of diabetic macular edema. Ophthalmology. 2015;122:1416–1425.
  • Pershing S, Enns EA, Matesic B, et al. Cost-effectiveness of treatment of diabetic macular edema. Ann Intern Med. 2014;160:18–29.
  • Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. mAbs. 2009;1:443–452.
  • Shukla AA, Thommes J. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol. 2010;28:253–261.
  • Shaughnessy AF. Monoclonal antibodies: magic bullets with a hefty price tag. BMJ. 2012;345:e8346.
  • Bandello F, Preziosa C, Querques G, et al. Update of intravitreal steroids for the treatment of diabetic macular edema. Ophthalmic Res. 2014;52:89–96.
  • Wang K, Wang Y, Gao L, et al. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull. 2008;31:1541–1546.
  • Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128:289–296.
  • Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31:915–923.
  • Callanan DG, Gupta S, Boyer DS, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 2013;120:1843–1851.
  • Boyer DS, Yoon YH, Belfort R Jr., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–1914.

••This study demonstrates the efficacy of sustained-release dexamethasone intravitreal implant in the management of diabetic macular edema

  • Agarwal A, Gupta V, Ram J, et al. Dexamethasone intravitreal implant during phacoemulsification. Ophthalmology. 2013; 120:211, 11 e1–5.

••This study demonstrated the role of dexamethasone implant in improving visual outcomes following cataract surgery in patients with diabetes.

  • Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121:2473–2481.
  • Tanito M, Hara K, Takai Y, et al. Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema. Invest Ophthalmol Vis Sci. 2011;52:7944–7948.
  • Arcinue CA, Ceron OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther. 2013;29:501–507.
  • Sadiq MA, Agarwal A, Soliman MK, et al. Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation. Expert Opin Drug Saf. 2015;14:1147–1156.
  • Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology. 2011;118:1580–1587.
  • Campochiaro PA, Hafiz G, Shah SM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology. 2010;117:1393–9 e3.
  • Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120:583–587.
  • Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125–2132.

•This clinical trial demonstrated the long-term benefit of the sustained-release next generation fluocinolone acetonide implant in the management of diabetic macular edema.

  • Schwartz SG, Flynn HW Jr., Scott IU. Intravitreal corticosteroids in the management of diabetic macular edema. Curr Ophthalmol Rep. 2013;1. doi:10.1007/s40135-013-0015-3.
  • Mason JO 3rd, Somaiya MD, Singh RJ. Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina. 2004;24:900–904.
  • Zhang X, Bao S, Lai D, et al. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes. 2008;57:1026–1033.
  • Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008; 115:1447–1449, 49 e1–10.
  • Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113:1533–1538.
  • Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–614.

•This clinical trial by the Diabetic Retinopathy Clinical Research Network demonstrated the superiority of ranibizumab over laser therapy for the treatment of diabetic macular edema over long term.

  • Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31:1009–1027.
  • Cho HY, Kang SW, Kim YT, et al. A three-year follow-up of intravitreal triamcinolone acetonide injection and macular laser photocoagulation for diffuse diabetic macular edema. Korean J Ophthalmol. 2012;26:362–368.
  • Lim JW, Lee HK, Shin MC. Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica. 2012;227:100–106.
  • Soheilian M, Garfami KH, Ramezani A, et al. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina. 2012;32:314–321.
  • Dmowski WP, Scholer HF, Mahesh VB, et al. Danazol-a synthetic steroid derivative with interesting physiologic properties. Fertil Steril. 1971;22:9–18.
  • Thomas GW, Rael LT, Bar-Or R, et al. Biphasic effect of danazol on human vascular endothelial cell permeability and f-actin cytoskeleton dynamics. Biochem Biophys Res Commun. 2012;421:707–712.
  • Waschke J, Curry FE, Adamson RH, et al. Regulation of actin dynamics is critical for endothelial barrier functions. Am J Physiol Heart Circ Physiol. 2005;288:H1296–305.
  • Vandenbroucke E, Mehta D, Minshall R, et al. Regulation of endothelial junctional permeability. Ann N Y Acad Sci. 2008;1123:134–145.
  • Efficacy and Safety Study to Evaluate Two Doses of Oral DMI-5207 in Adult Subjects with Diabetic Macular Edema. 2013; [cited 2015 Jul 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT02002403
  • A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug) in the Treatment of Diabetic Macular Edema. 2014; [cited 2015 Jul 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT01821677
  • Ampio Pharmaceuticals Announces Positive Study Results on Optina for the Treatment of Diabetic Macular Edema. 2015; [cited 2015 Jul 28]. Available from: http://ampiopharma.com/news/ampio-pharmaceuticals-announces-positive-study-results-on-optina-for-the-treatment-of-diabetic-macular-edema/
  • Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin. 2006;22:397–404.
  • Modi SS, Lehmann RP, Walters TR, et al. Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study. J Cataract Refract Surg. 2014;40:203–211.
  • Kern TS, Miller CM, Du Y, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes. 2007;56:373–379.
  • Hariprasad SM, Callanan D, Gainey S, et al. Warren K. Cystoid and diabetic macular edema treated with nepafenac 0.1%. J Ocul Pharm Ther. 2007;23:585–590.
  • Callanan D, Williams P. Topical nepafenac in the treatment of diabetic macular edema. Clin Ophthalmol. 2008;2:689–692.
  • Tzelikis PF, Vieira M, Hida WT, et al. Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo-controlled randomised study. Br J Ophthalmol. 2015;99:654–658.
  • Friedman SM, Almukhtar TH, Baker CW, et al. Topical nepafenec in eyes with noncentral diabetic macular edema. Retina. 2015;35:944–956.
  • Topical Nepafenac as Supplement for Diabetic Macular Edema. 2015; [cited 2015 Jul 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT02443012
  • Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema (NEVANAC). 2008; [cited 2015 Jul 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT00780780
  • Russo A, Costagliola C, Delcassi L, et al. Topical nonsteroidal anti-inflammatory drugs for macular edema. Mediators Inflamm. 2013;2013:476525.
  • Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55:108–133.
  • Henderson BA, Gayton JL, Chandler SP, et al. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain. Ophthalmology. 2011;118:2120–2127.
  • Walters TR, Goldberg DF, Peace JH, et al. Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials. Ophthalmology. 2014;121:25–33.
  • Rajpal RK, Ross B, Rajpal SD, et al. Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence. Patient Prefer Adherence. 2014;8:925–931.
  • Endo N, Kato S, Haruyama K, et al. Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica. 2010;88:896–900.
  • Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema. 2009; [cited 2015 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT00758628
  • Sahoo S, Barua A, Myint KT, et al. Topical non-steroidal anti-inflammatory agents for diabetic cystoid macular oedema. Cochrane Database Syst Rev. 2015;2:CD010009. doi:10.1002/14651858.CD010009.pub2.

••This comprehensive systematic review elucidates the present role of topical non-steroidal anti-inflammatory drug therapy in the management of diabetic macular edema.

  • Shen J, Frye M, Lee BL, et al. Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J Clin Invest. 2014;124:4564–4576.
  • Campochiaro PA, Sophie R, Tolentino M, et al. Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. Ophthalmology. 2015;122:545–554.

••This study provides evidence of usefulness of targeting the TIE2 angiogenic pathway for treating diabetic macular edema.

  • The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema. 2014; [cited 2015 Jul 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02050828
  • Pluckthun A. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu Rev Pharmacol Toxicol. 2015;55:489–511.
  • Campochiaro PA, Channa R, Berger BB, et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol. 2013; 155: 697–704, 04 e1–2.

••This multicenter clinical trial established the efficacy of designed ankyrin repeat proteins (DARPins), a novel class of drugs, in treating macular edema due to diabetes.

  • A Study of Abicipar Pegol in Patients With Diabetic Macular Edema. 2014; [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02186119
  • Safety and Efficacy of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration. 2015; [cited 2015 Jul 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT02462486
  • Noda K, Nakao S, Zandi S, et al. Vascular adhesion protein-1 regulates leukocyte transmigration rate in the retina during diabetes. Exp Eye Res. 2009;89:774–781.
  • Yoshikawa N, Noda K, Ozawa Y, et al. Blockade of vascular adhesion protein-1 attenuates choroidal neovascularization. Mol Vis. 2012;18:593–600.
  • A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) (VIDI). 2015; [cited 2015 Jul 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT02302079
  • Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007;50:17–24.
  • Chen M, Liu A, Ouyang Y, et al. Fasudil and its analogs: a new powerful weapon in the long war against central nervous system disorders? Expert Opin Investig Drugs. 2013;22:537–550.
  • Shi J, Wei L. Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil. J Cardiovasc Pharmacol. 2013;62:341–354.
  • Arita R, Hata Y, Nakao S, et al. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes. 2009;58:215–226.
  • Yokota T, Utsunomiya K, Taniguchi K, et al. Involvement of the Rho/Rho kinase signaling pathway in platelet-derived growth factor BB-induced vascular endothelial growth factor expression in diabetic rat retina. Jpn J Ophthalmol. 2007;51:424–430.
  • Ahmadieh H, Nourinia R, Hafezi-Moghadam A. Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema: a novel treatment. JAMA Ophthalmol. 2013;131:923–924.
  • Nourinia R, Ahmadieh H, Shahheidari MH, et al. Intravitreal fasudil combined with bevacizumab for treatment of refractory diabetic macular edema; a pilot study. J Ophthalmic Vis Sci. 2013;8:337–340.
  • Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema. 2013; [cited 2015 Jul 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT01823081
  • Bansal D, Badhan Y, Gudala K, et al. Ruboxistaurin for the treatment of diabetic peripheral neuropathy: a systematic review of randomized clinical trials. Diabetes Metab J. 2013;37:375–384.
  • Aiello LP, Clermont A, Arora V, et al. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci. 2006;47:86–92.
  • Aiello LP, Vignati L, Sheetz MJ, et al. Oral protein kinase c beta inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study 2. Retina. 2011;31:2084–2094.
  • Sheetz MJ, Aiello LP, Shahri N, et al. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2). Retina. 2011;31:1053–1059.
  • The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes. 2005;54:2188–2197.
  • Aiello LP, Davis MD, Girach A, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology. 2006;113:2221–2230.
  • Sheetz MJ, Aiello LP, Davis MD, et al. The effect of the oral PKC beta inhibitor ruboxistaurin on vision loss in two phase 3 studies. Invest Ophthalmol Vis Sci. 2013;54:1750–1757.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.